SA

Sumalatha Ambarapu

Active Director Director DIN 10272329
DIN 10272329 First appointment Aug 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2023
Shareholding value •••• Premium profile

About Sumalatha Ambarapu

Data last updated:

Sumalatha Ambarapu is a Director at Hatri Pharma Private Limited (since 2023). The company operates in Pharma. Hatri Pharma Private Limited reported revenue of ₹71.7 Lakh (FY 2025).

DIN 10272329
Primary Designation Director
Industry Pharma
First Appointment 09 Aug 2023
Oldest Company Age 16 yrs
Largest company Hatri Pharma Private Limited · ₹71.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hatri Pharma Private Limited U24232TS2010PTC205106
Director09 Aug 20232010₹71.7 Lakh (FY 2025)Active

Board colleagues of Sumalatha Ambarapu

Directorship timeline

Open interactive timeline →
Hatri Pharma Private Limited
Premium access

Shareholding and investment profile for Sumalatha Ambarapu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sumalatha Ambarapu

Sumalatha Ambarapu currently holds 1 directorship: Hatri Pharma Private Limited (Director, since 09 Aug 2023, revenue ₹71.7 Lakh (FY 2025)).

Sumalatha Ambarapu was first appointed on 09 Aug 2023 as Director at Hatri Pharma Private Limited.

The current boards of Sumalatha Ambarapu's companies include Mohan Reddy Enaganuri (Hatri Pharma Private Limited), Rebala Rupakala (Hatri Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available